Floatz logo

Dfn-15

Arthritis

ARKAY TherapeuticsPhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Arthritis cohort.

Asset / SponsorPhaseRating
PROPOFOL
Pedro Paulo Tanaka
Phase 4BB
Desflurane
Pedro Paulo Tanaka
Phase 4BB
Xeomin®
Minneapolis Veterans Affairs Medical Center
Phase 2CCC
Metformin
ARKAY Therapeutics
Phase 1/2CCC
VALSARTAN
ARKAY Therapeutics
Phase 1/2CCC

View all 22 →

Same molecule, other indications

Dfn-15 is also rated in:

osteoarthritis, hipDormant
BB
Indicative ·
71 / 100
View asset →
osteoarthritis, kneeDormant
BB
Indicative ·
69 / 100
View asset →
bipolar depressionDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →